Solid Biosciences (SLDB) EBIT Margin: 2022-2024
Historic EBIT Margin for Solid Biosciences (SLDB) over the last 2 years, with Dec 2024 value amounting to 53,194.67%.
- Solid Biosciences' EBIT Margin rose 3115011.00% to 53,194.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 38,155.29%, marking a year-over-year increase of 1440769.00%. This contributed to the annual value of 38,155.29% for FY2024, which is 1446166.00% up from last year.
- As of Q4 2024, Solid Biosciences' EBIT Margin stood at 53,194.67%, which was up 23.98% from 42,904.88% recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' EBIT Margin registered a high of 53,194.67% during Q4 2024, and its lowest value of -1,318.03% during Q2 2022.
- For the 3-year period, Solid Biosciences' EBIT Margin averaged around 27,682.08%, with its median value being 26,471.07% (2023).
- Data for Solid Biosciences' EBIT Margin shows a peak YoY skyrocketed of 3,115,011bps (in 2024) over the last 5 years.
- Over the past 3 years, Solid Biosciences' EBIT Margin (Quarterly) stood at -1,318.03% in 2022, then skyrocketed by 2,550,091bps to 22,044.55% in 2023, then skyrocketed by 3,115,011bps to 53,194.67% in 2024.
- Its last three reported values are 53,194.67% in Q4 2024, 42,904.88% for Q3 2024, and 31,577.27% during Q2 2024.